未知生产厂商
VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. The OMVs contain over 100 proteins, and are derived from meningococcal group B and capsular polysaccharide of meningococcal group C. As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C. This vaccine causes induction of bactericidal antibodies with broad cross-reactivity. Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study. This vaccine may also induce moderate protection against N. gonorrhoeae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. The OMVs contain over 100 proteins, and are derived from meningococcal group B and capsular polysaccharide of meningococcal group C. As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C. This vaccine causes induction of bactericidal antibodies with broad cross-reactivity. Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study. This vaccine may also induce moderate protection against N. gonorrhoeae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
